An endometrial cancer clinical trial Wednesday, July 19, 2023 An international study has now opened in Canada that will evaluate if immunotherapy prevents tumour recurrence or spread in early-stage endometrial cancer. The researchers want to compare the effects of a new drug in combination with radiation therapy compared to the current standard treatment of radiation therapy alone for endometrial cancer. “This study represents an important opportunity to rigorously test a personalized immunotherapy treatment strategy based on tumour biology as defined by state of the art molecular testing. The impact of this study will be transformative for the gynaecology community based on the training, education and knowledge translation that will occur throughout the study lifecycle,” says Dr Wendy Parulekar, CCTG Senior Investigator. The new drug has been developed for the treatment of one sub-type of endometrial cancer and early tests show that it may help slow the growth of endometrial cancer but it is not clear if it can offer better survival and quality of life results than standard treatment. Refining Adjuvant Treatment in Endometrial Cancer Based On Molecular Features (RAINBO) is an international study led by the Dutch Gynecologic Oncology Group, seeks to determine if a immunotherapy drug, prevents recurrence or spread when given during and after post-surgery radiotherapy and will provide important information on how the drug affects overall survival, side effects, and quality of life. Endometrial cancer is the most common gynecologic malignancy and the fourth most-commonly diagnosed cancer in Canadian women. Immunotherapy has proven to be effective for mismatch repair deficiency (MMRd) endometrial cancer, a relatively rare but important subgroup of cancers, which has spread beyond the uterus and has not traditionally responded to chemotherapy. The study in Canada was made possible through the support of the CIHR Project Grant program the Canadian Cancer Society and pharmaceutical support from Aztra Zeneca Global. For more information about the CCTG EN11 study please visit: www.clinicaltrials.gov (NCT05255653) or the CCTG EN11 members trial page or the CCTG EN11 patient information page. Dr Stephen Welch, Regional Cancer Center in London Ontario and EN11 study chair Dr Wendy Parulekar, CCTG Senior Investigator
